EFFECT OF SIMVASTATIN ON GEFITINIB RESISTANCE IN NON-SMALL CELL LUNG CANCER WITH THE T790M MUTATION OF EPIDERMAL GROWTH FACTOR RECEPTOR

被引：0
|
作者：
Kim, Hak R. [1 ]
Hwang, Ki-Eun [1 ]
Jeong, Eun-Taik [1 ]
机构：
[1] Wonkwang Univ, Sch Med, Dept Internal Med, Iksan, Jeonbuk, South Korea
来源：
RESPIROLOGY | 2013年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：150 / 150
页数：1
相关论文
共 50 条
  • [41] EGFR T790M resistance mutation in non small-cell lung carcinoma
    Denis, Marc G.
    Vallee, Audrey
    Theoleyre, Sandrine
    [J]. CLINICA CHIMICA ACTA, 2015, 444 : 81 - 85
  • [42] Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer
    Prim, Nathalie
    Quoix, Elisabeth
    Beau-Faller, Michele
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (09) : 1615 - 1616
  • [43] Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
    Saad, Nibal
    Poudel, Aarati
    Basnet, Alina
    Gajra, Ajeet
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 1757 - 1765
  • [44] Combined Treatment with Epimedium koreanum Nakai Extract and Gefitinib Overcomes Drug Resistance Caused by T790M Mutation in Non-Small Cell Lung Cancer Cells
    Song, Jie
    Zhong, Rongling
    Huang, Houcai
    Zhang, Zhenhai
    Ding, Dongmei
    Yan, Hongmei
    Sun, E.
    Jia, Xiaobin
    [J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2014, 66 (04): : 682 - 689
  • [45] Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib
    Shinno, Y.
    Goto, Y.
    Sato, J.
    Morita, R.
    Matsumoto, Y.
    Murakami, S.
    Kanda, S.
    Horinouchi, H.
    Fujiwara, Y.
    Yamamoto, N.
    Ohe, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [46] Best practices in epidermal growth factor receptor T790M testing for advanced non-small-cell lung cancer in Hong Kong
    Nyaw, Jonathan S. F.
    Cheung, K. M.
    Hioe, F.
    Kam, Michael T. Y.
    Lau, Johnny K. S.
    Lau, Y. M.
    Leung, Dennis K. C.
    Lim, Fiona M. Y.
    [J]. HONG KONG MEDICAL JOURNAL, 2023, 29 (03) : 240 - 246
  • [47] Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation
    Liam, Chong-Kin
    Poh, Mau-Ern
    Liam, Yong-Sheng
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 : S1847 - S1851
  • [48] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [49] Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
    Chang, Gee-Chen
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Chao, Heng-Sheng
    Yang, Cheng-Ta
    Lin, Chien-Chung
    Hung, Jen-Yu
    Hsiao, Sheng-Yen
    Wang, Chin-Chou
    Chian, Chih-Feng
    Hsia, Te-Chun
    Chen, Yuh-Min
    [J]. PLOS ONE, 2024, 19 (05):
  • [50] Plasma T790M Mutation Associates with Extensive Progression in Non-small Cell Lung Cancer with Acquired Resistance to EGFR Inhibitors
    Zhang, Shirong
    Zhu, Lucheng
    Xia, Bing
    Chen, Enguo
    Zhao, Qiong
    Chen, Xueqin
    Wang, Limin
    Jiang, Hong
    Chen, Xufeng
    Ma, Shenglin
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1251 - S1252
12345